**In Vitro Assessment of Platelet Lesions during 5-day Storage in Iranian Blood Transfusion Organization (IBTO) Centers**

Behruz Ghezelbash MSc, Sedigheh Amini kafiabad MD, Mohammad Taher Hojjati MSc, Mohsen Hamidpoor PhD, Shahram Vaeli MD, Mohammad Reza Tabtabae MS, Ahmad Gharehbaghian PhD

**Abstract**

**Background and Objectives:** Platelet concentrates (PC) are used in thrombocytopenia and inherited or acquired platelet dysfunction disorders. Thus, retaining the platelets quality and function during storage will lead to desirable outcomes in treatment of such patients. **Methods:** In this study, we evaluated 40 PC bags, prepared by PRP method in IBTO centers. We applied an array of assays, on first, third and fifth days of storage for PC quality control, including swirling, cell counting, bacterial contamination, measurement of CD62P, pH, and platelet aggregation test, to evaluate platelet lesion during storage. **Results:** All units were negative for bacterial contamination. Swirling was positive for all units on various days; platelet count was in the acceptable range. Measurement of CD62P on fifth day was not significantly higher than third or first day ($P > 0.15$) ($P > 0.05$). pH on fifth day was significantly lower than first day ($P < 0.01$) ($P < 0.05$). Platelet aggregation with arachidonic acid and ristocetin showed significant decrease on fifth day compared to third day ($P < 0.01$) ($P < 0.05$). **Conclusions:** CD62P associated with other platelet function tests can be used as an activation marker in evaluation of PC functions during storage.

**Keywords:** CD62P, platelet lesion, platelet storage


**Introduction**

Although the ability to produce a platelet concentrate (PC) for transfusion purposes has existed for more than 50 years, this product still presents one of the major challenges to the blood banks, because of its limitations of storing under standard blood bank conditions. Depending on the jurisdiction, platelets have a maximum storage time of 3 to 7 days. During PC storage, a variety of changes occurs in platelets, including the expression of GPIb, GPIIb/IIIa, producing platelet activation markers (CD40L, CD63, and CD62P), membrane phospholipids inversion and exposure of phospholipids with negative charge, and platelet derived micro-particles formation. CD62P (P-selectin), a membrane molecule is expressed on the cell surface. Increasing membrane expression of CD62P, as well as increased levels in plasma, is therefore indicative of platelet activation. Evaluation of platelet activation in response to agonists is also another factor in evaluation of platelet activation. After encountering these agonists, platelets initiate secreting granules contents to the outside which consequently leads to aggregation. In this study, we evaluated the main biochemical and activation markers changes in PC during storage in IBTO centers for a period of six months.

**Material and Methods**

This was a cross-sectional study and the samples were obtained from IBTO centers. In this study, 40 samples were collected from IBTO centers. According to IBTO protocols, Quality Control (QC) must be performed in one percent of products of each center. The sample is randomly selected and QC is done according to IBTO standard operating procedure (SOP). Moreover, measuring CD62P, response to agonists and platelet aggregation tests is done on each sample. During the tests, all samples are kept in platelet shaker at the authorized temperature (20–24°C) and in a closed system. All PC examinations took place on the first day after preparation for volume measurement, Platelet count, pH measurement, swirling, CD62P and aggregation tests. On the third and fifth days, we repeated swirling, pH, CD62P and aggregation test for all bags. Evaluation of microbial contamination was also performed for each sample in tioglycolate medium, and monitored for five days after preparation. For microbial culture, 1 mL of PC was added to 10 mL of tioglycolate medium and incubated at 37°C for 7 days. During this time, the media was monitored on a daily basis for turbid appearance (indication of positive culture). PC volume was estimated by multiplying each bag’s weight by 1.03. Swirling was induced by gently rotating or tapping a platelet bag in front
of a light source. CD62P was measured by flow cytometry according to the manufacturer’s procedure (Immunocytometry System, Becton Dickinson, Belgium). Approximately 2 mL of PRP samples was collected from each bag. Platelet samples studied were diluted to a volume of PRP + three volumes phosphate buffer solution (PBS). Then, three tubes were prepared for testing. The first tube was added 5 μL antibody (Becton Dickinson BD) negative control isotype, the second tube 5 μL CD41 antibody conjugated with PE ((F0803 Dako) mouse monoclonal anti-CD41 human platelets and the third tube 5 μL CD62P antibody conjugated with FITC (BD PHarminogen FITC) mouse anti-human CD62P. Up to 50 μL prepared samples were added to tubes containing antibodies. The three tubes were reacted for 30 min away from light, and then mixed with 1 mL of 1% paraformaldehyde at 4°C. After sample preparation procedures, testing with flow cytometry assay (Becton-Dickinson) was performed. For each sample run, data were acquired for 10,000 events gated on forward and side-angle light scatter with gains adjusted to include the platelet population. The percentage of CD62P gate activated platelets was determined according to the manufacturer’s procedure (Immunocytometry System, Becton Dickinson, Belgium). Approximately 2 mL of PRP + three volumes phosphate buffer so-

**Table 1.** Results of changes in pH, CD62P and platelet aggregation test in five-day storage of PC in IBTO centers.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Day one</th>
<th>Day three</th>
<th>Day five</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>0.35 ± 7.46</td>
<td>8.26 ± 21.93</td>
<td>0.3 ± ± 7.34</td>
</tr>
<tr>
<td>CD62P</td>
<td>7.94 ± 19.07</td>
<td>18.9 ± ± 54.9</td>
<td>23.7 ± ± 41</td>
</tr>
<tr>
<td>% aggregation by arachidonic acid</td>
<td>22.6 ± 67.6</td>
<td>16.6 ± 70.29</td>
<td></td>
</tr>
<tr>
<td>% aggregation by ristocetin</td>
<td>6.44 ± 83.2</td>
<td>18.9 ± 54.9</td>
<td>23.7 ± 41</td>
</tr>
</tbody>
</table>

The mean volume of PC units was 57 mL. Microbial cultures for all samples were negative during 5-day storage. In addition, all samples had optimal swirling on the first, third and fifth days of storage for each unit. Mean platelet count in three IBTO regional center were $5.9 \times 10^{10}$. The results for pH, CD62P and aggregometry are presented in Table 1. According to the results, pH had significant change ($P < 0.01$) and decreased during the storage time, but it was in the authorized range. CD62P measurement had no significant changes between day one, day three and day five ($P > 0.15$) and only had a mild elevation.

In aggregation test, response to arachidonic acid was significant on day three and day five, compared to day one. In response to Ristocetin, on days one and three, the value was not significant ($P > 0.17$), but it was significant on day five compared to day three ($P < 0.01$) and had mild elevation.

**Discussion**

During preparation and storage, PC undergoes metabolic and morphologic changes that leave undesirable effect on platelet structure and functions, causing poor outcomes after transfusion. The aim of this study was to evaluate morphological and biochemical alternations in PC during storage at 22°C, as a program of QC in IBTO centers. According to international standards, CPD-A1 is used as anticoagulant in bags, and PC is prepared by PRP method, the commonest PC preparation method in the world. The mean volume of PC per bag in the three centers was 57 mL and the mean platelet count was $5.8 \times 10^{10}$. Although smaller volume does not affect platelet functions, reduced plasma volume in PC, causing decrease in platelets movements in bags, increases the incidence of direct contacts of platelets to each other. These contacts leads to activation and aggregation of platelets before transfusion, and consequently aggregated platelets filtrate by transfusion sets and undesirable platelet count will achieve in patients after transfusion. This condition increases the demand for more PC, and increases the incidence of adverse effect of platelet transfusion like being refractory to platelet transfusion. The swirling score, done as a rapid inexpensive quality control measure, was assessed in our study. Swirling has a direct correlation with pH and function of platelets. Functional platelets have a discoid morphology, which allows them in this form appearance waves or hurricane can be seen with the naked eye. For evaluation of temperature effects on swirling of platelets in PC, Gabriele and colleagues compared swirling at 4°C and 22°C. Their results showed that swirling at 4°C was negative, but it was positive at 22°C. In our study, swirling was positive in PC during storage that indicates its preparation and storage was done in a good condition in these centers. Over the years, improvements in donor screening has nearly eliminated hepatitis B virus, hepatitis C virus and HIV from many countries’ blood supply. As the transfusion-transmission rates of these agents decreased, platelet bacterial contamination assumed a new noticeable role as the most frequent infectious risk of transfusion. Unlike other products such as red cell and FFP, while room temperature storage allows transfused platelets to circulate in vivo, it has the negative side of promoting bacterial growth. Because of this risk, platelet storage is ordinarily limited to only 5 days, making platelet...
inventory management extremely challenging.\textsuperscript{13,14} In our study, microbial culture was negative during storage. Whereas, potential sources of contamination transfer from the venopuncture site into bags, the proper education of staff engaged in PC production has a crucial role in safety of blood. Platelet aggregation responses to a number of agonists drop significantly during storage. In our study, a significant decrease was observed in response to agonists on day five compared to day three and day one. In similar studies, Kocazeybec, et al.\textsuperscript{15} and Holger, et al.\textsuperscript{16} reported similar results to our study. Their results showed a significant decline in response to agonist on day five. One of the most important changes in PC during storage is platelet activation, whereby the function and survival of platelets will decline. One of useful platelet activation markers is CD62P. Platelet surface CD62P is a marker for the detection of circulating degranulated platelets in clinical settings. The expression of CD62P has been shown to be inversely correlated with recovery of platelets and platelet count increment, because of triggering fast CD62-mediated platelet clearance. In our study, there was no significant change in CD62P value between three times of evaluation during storage time.\textsuperscript{17} Michelson et al. demonstrated that circulating degranulated platelets rapidly lose surface CD62P to the plasma pool, indicating that platelet surface CD62P is not an ideal marker for the detection of circulating degranulated platelets although it may still be a useful marker of platelet degranulation if there is continuous activation of platelets.\textsuperscript{18} Previous studies suggested that the plasma concentration of soluble CD62P could be used as a marker of platelet activation in clinical settings, although an increase in the plasma concentration may also reflect the release of CD62P from activated and/or damaged endothelial cells.\textsuperscript{19} Although these studies indicated the relative role of CD62P as an indicator of platelet activation \textit{in vivo}, it should not be neglected that we are measuring this marker \textit{in vitro}, where no mechanism of elimination of this marker is available and the system is closed. Thus, CD62P can be a good predictor of activation in PC during storage. Similar to our study, gentle elevation of CD62P in PC was reported by Meltem et al.\textsuperscript{20} In another study, Nie and colleagues.\textsuperscript{21} reported no significant changes in CD62P value in PC in the first 72 hours after preparation with a mild elevation occurring after day three, and these are similar to our findings. As expected, according to the results of other related tests in our study, none of the PC under study underwent platelet activation and their transfusion can be safe and effective to patient to achieve the ideal CCI.

\textbf{Acknowledgment}

We are thankful to flowcytometry, coagulation and QC Laboratory of IBTO for their continued support and collaborations.

\textbf{References}